Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections. Co.'s product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial pulmonary disease. Co.'s partnership-directed programs consist of tebipenem pivoxil hydrobromide, which is designed to be oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections; and SPR206, which is an IV-administered antibiotic being developed as an option to treat multi-drug resistant Gram-negative bacterial infections in the hospital setting. When considering the Spero Therapeutics Inc stock dividend history, we have taken known splits into account, such that the SPRO dividend history is presented on a split-adjusted ("apples to apples") basis. Spero Therapeutics Inc dividend history is presented both in graphical/chart form, and as a SPRO dividend history data table along the right-hand column.
|
SPRO Stock Dividend HistoryThe SPRO dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable SPRO historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the SPRO dividend history record. Also see the SPRO stock dividend history data table along the right-hand column below. |
|
SPRO Next Dividend Date » (Projection based upon history) SPRO Dividend Growth Rate » Quotes delayed 20 minutes |
Buy (3.33 out of 4) 50th percentile
(ranked higher than approx. 50% of all stocks covered)
Analysts' Target Price: SPRO Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection: SPRO Next Dividend Date Chart: SPRO Chart - 5Yr Dividend Yield |